

WHITE PAPER

A comprehensive rapid test for major severe respiratory virus in Hong Kong: product performance test among major brands

Zhi Zheng, Vic Lu, Gavin Wang, Sylvanna Lam, Kent Cheng, Ricky Chiu
PHASE Scientific International Limited, Hong Kong, China __ ricky.chiu@phasesci.com

Abstract

Respiratory illnesses have continued to be one of the world's most pressing healthcare issues since the COVID-19 pandemic. However, since common contagious respiratory illnesses caused by SARS-CoV-2, influenza viruses, respiratory syncytial virus (RSV), adenoviruses (AdV) and/or Mycoplasma (MP) all share similar symptoms, distinguishing them can be difficult and may lead to inaccurate treatment decisions. Additionally, according to the Centers for Disease Control and Prevention (CDC), people can be co-infected with multiple viruses simultaneously. Therefore, it is crucial to have rapid diagnostic tests that can detect and differentiate between contagious respiratory infections, allowing for early and accurate treatment to be provided for patients before symptoms worsen. PHASE Scientific has developed the INDICAID™ RESPIRATORY 6-in-1 Rapid Antigen Test (INDICAID™) for the detection and differentiation of SARS-CoV-2, Influenza A/B, RSV, AdV viral and MP antigens. The sensitivity of the Rapid Antigen Test (RAT) is the most important performance metric for accurate detection. This study is to evaluate the Limit of Detection (LoD) for a total of 11 community existing strains of influenza A, B, SARS-CoV-2, RSV, AdV and MP of three major brands of RATs in Hong Kong: 1) INDICAID™ RESPIRATORY 6-in-1 Rapid Antigen Test, 2) BioTeke™ SARS-CoV-2/FluA/FluB/RSV/ADV/MP Antigen Test Kit (SARS-CoV-2 | Flu A | Flu B | RSV | ADV | MP), 3) REAGEN® SARS-CoV-2/RSV/ADV/MP&FluA/B Antigen Rapid Test Kit. For Influenza A (H1N1), INDICAID™ exhibits 4 times better LoD than BioTeke™, while REAGEN® was not able to produce a definite positive test result in all concentrations of the virus tested. For Influenza A (H3N2), INDICAID™ exhibits 2 times better LoD than BioTeke™ and REAGEN®. For Influenza B (Victoria) B/Colorado/06/2017 strain, INDICAID™ exhibits 2 times better LoD than BioTeke™. For the Influenza B (Yamagata) B/Phuket/3073/2013 strain, INDICAID™ exhibits the same LoD as BioTeke™. REAGEN® showed poorer performance in both Influenza B strains and was not able to produce a definite positive test result in all concentrations of the virus tested. For SARS-CoV-2 USA-WA1/2020 strain, INDICAID™ exhibits 1.6 times better LoD than BioTeke™. For SARS-CoV-2 USA/CA-Stanford-109_S21/2022 strain, INDICAID™ showed a similar performance to BioTeke™ while REAGEN® were not able to produce a definite positive test result in all concentrations of the virus tested. REAGEN® showed poorer performance in both SARS-CoV-2 strains and was not able to produce a definite positive test result in all concentrations of the virus tested. For Respiratory syncytial virus A (RSV-A) strain, INDICAID™ exhibits 4 times better LoD than REAGEN®, and showed similar performance as BioTeke™. For Respiratory syncytial virus B (RSV-B) strain, INDICAID™ showed 4 times and 2 times better LoD than REAGEN® and BioTeke™ respectively. For AdV Type 1 strain, INDICAID™ exhibits 2 times better LoD than the other 2 brands. For AdV Type 7A, INDICAID™ showed a similar performance to BioTeke™ while REAGEN® were not able to produce a definite positive test result in all concentrations of the virus tested. For Mycoplasma pneumoniae, INDICAID™ exhibits 4 times better LoD than BioTeke™, while REAGEN® were not able to produce a definite positive test result in all concentrations of the MP tested. In this study, REAGEN® was unable to produce a definite positive test result for 7 out of 11 virus strains at all concentrations tested, and therefore no LoD value was determined in the presented data. The overall performance of the INDICAID™ RESPIRATORY 6-in-1 Rapid Antigen Test is better than BioTeke™ and REAGEN® in detecting the most common strains of SARS-CoV-2, Influenza A/B, RSV, AdV, and MP.

Introduction

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in December 2019 and rapidly spread worldwide before the World Health Organization (WHO) declared it a global pandemic (1). As of July 2023, over 767 million cases of COVID-19 with 6 million deaths have been reported (2). Symptoms include coughs, fevers, chills, headaches, ageusia, anosmia, myalgia, nausea, vomiting, diarrhea, dyspnea, malaise, anorexia, and fatigue (3). Severe cases can lead to respiratory, neurological, cardiovascular, and renal complications, ultimately resulting in death. Current drug treatments target molecules involved in the invasion of SARS-CoV-2 into the host cell or molecules associated with SARS-CoV-2 viral replication inside the host (1).

Influenza viruses are categorized into four types: influenza A, B, C, and D. Influenza A and B infect humans and cause seasonal flu. Influenza A is further divided into several subtypes based on the antigenicity and the combination of hemagglutinin (HA) and neuraminidase (NA) present on the virus. Currently circulating subtypes include H1N1 and H3N2. Influenza B is classified into two lineages: B/Yamagata and B/Victoria (4). Clinical presentation of influenza includes dry cough, sneezing, nasal discharge, fever, headache, myalgia, lacrimation, burning sensation in the eyes, chills, malaise, and anorexia. Fatalities resulting

from influenza are caused by respiratory, musculoskeletal, neurological, and cardiovascular complications (3). Known drug treatments for influenza inhibit the structural and functional proteins of the virus or interfere with influenza virus replication within the host cell (1) and have been shown to be effective in reducing complications.

Respiratory syncytial virus (RSV) mainly causes lower respiratory tract infections such as bronchiolitis and pneumonia in infants under 6 months old and upper respiratory tract infections such as rhinitis and colds in older children and adults. RSV infection is the leading cause of hospitalization for viral respiratory tract infections in infants and young children, posing a serious health hazard, especially for premature infants, infants with congenital heart disease, or primary immune deficiency (6). RSV infection causes minor damage to the ciliated epithelial cells of the respiratory tract but can lead to bronchiolitis, pneumonia, and other serious respiratory diseases in infants aged 2 to 6 months.

Adenovirus (AdV) can infect the respiratory tract, gastrointestinal tract, urethra and bladder, eyes, liver, etc. Typical symptoms of respiratory infections include cough, nasal congestion, and pharyngitis, accompanied by fever, chills, headache, and muscle pain. There are four different syndromes associated with AdV, including acute febrile

A comprehensive rapid test for major severe respiratory virus in Hong Kong; product performance test among major brands

pharyngoconjunctival fever, acute respiratory diseases, ARD, pneumonia (7).

Mycoplasma(MP) is a bacterium (singular form of bacteria) that causes infections. There are different types of mycoplasma that target specific locations in your body including your respiratory, urinary and genital tracts. Mycoplasma pneumoniae most commonly affects children between the ages of 5 and 9. Outbreaks are also frequent in group environments like residence halls or nursing homes where bacteria can easily spread from person to person. Symptoms of mycoplasma pneumoniae infections can last for just a few days or up to a month and the common symptoms of mycoplasma pneumoniae infections include: Dry cough, Fatigue, Fever, Headache Which are similar to the Flu. MP is not sensitive to cephalosporin, penicillin and other antibiotics, while tetracycline and macrolides have good therapeutic effects on it, so the diagnosis of mycoplasma is of great value for the selection of treatment.

Rapid Antigen Tests play a crucial role in early identification of the specific pathogens causing respiratory infections, enabling timely administration of appropriate medication and effective measures to protect others. RATs with higher sensitivity provide enhanced capabilities for detecting diseases in their early stages. Our study aims to assess the disparity in detection sensitivity between INDICAID™ products and other widely available RATs in the market. By conducting this evaluation, we seek to determine the performance differences and potential advantages of the INDICAID™ products in accurately detecting respiratory infections at an early stage.

The INDICAID™ RESPIRATORY 6-in-1 Rapid Antigen Test developed by PHASE Scientific International Ltd, the BioTeke™ SARS-CoV-2/FluA/FluB/RSV/ADV/MP Antigen Test Kit (SARS-CoV-2 | Flu A | Flu B | RSV | ADV | MP) developed by BioTeke Corporation (Wuxi) Co., Ltd., the REAGEN® SARS-CoV-2/RSV/ADV/MP&FluA/B Antigen Rapid Test Kit manufactured by Shenzhen Reagent Technology Co., Ltd. were included in this study. The objective of the study was to compare the analytical sensitivity using commercially available virus culture fluid.

Testing Materials

Manufacturer	Product Number	Description	Stock Concentration (from Certificate of Analysis from supplier)
ZeptoMetrix®	0810165CF	Influenza A (H1N1) A/California/7/2009	1.41×10 ⁵ TCID ₅₀ /mL
ZeptoMetrix®	0810240CF	Influenza A (H3N2) A/Victoria/361/2011	3.89×10 ⁴ TCID ₅₀ /mL
ZeptoMetrix®	0810573CF	Influenza B (Victoria) B/Colorado/06/2017	1.17×10 ⁵ TCID ₅₀ /mL
ZeptoMetrix®	0810515CF	Influenza B (Yamagata) B/Phuket/3073/2013	1.86×10 ⁴ TCID ₅₀ /mL
ZeptoMetrix®	0810587UV	SARS-CoV-2 USA-WA1/2020	1.51×10 ⁶ TCID ₅₀ /mL
ZeptoMetrix®	0810665CFHI	SARS-CoV-2 Lineage XBB; Omicron Var. USA/CA-Stanford-109_S21/2022	5.95×10 ⁶ TCID ₅₀ /mL
ZeptoMetrix®	0810040ACF	Respiratory syncytial virus A	5.01x10 ⁵ TCID ₅₀ /mL
ZeptoMetrix®	0810040CF	Respiratory syncytial virus B	3.16x10 ⁶ TCID ₅₀ /mL
ZeptoMetrix®	0810050CF	Adenovirus Type 1	2.82x10 ⁷ TCID ₅₀ /mL
ZeptoMetrix®	0810021CF	Adenovirus Type 7A	3.16x10 ⁶ TCID ₅₀ /mL
ZeptoMetrix®	0801579	Mycoplasma pneumoniae	3.16 x 10 ⁸ CCU/mL
Lee Biosolutions	991-26-P	Pooled Human Donors Nasal Wash - Normal	Not Available

Methods

Limit of detection (LoD) determination:

INDICAID™ RESPIRATORY 6-in-1 Rapid Antigen Test LoD was determined for SARS-CoV-2, influenza A&B, RSV, AdV and MP using analyte from two strains of each virus. This testing processes utilized a contrived sample matrix consisting of pooled human donors' nasal wash (PNW) obtained from Lee Biosolutions, MO, USA. In this study, the INDICAID™ kit was used to test the stock pooled negative nasal wash (PNW) samples in three replicates. All three replicates tested negative for all viruses, indicating that the stock PNW was classified as negative.

The virus culture fluid, obtained from Zeptomatrix, NY, USA, had a predetermined concentration of the virus as provided by the supplier. Each strain of the virus was independently added to PNW and diluted to various concentrations using PNW. The LoD was determined by testing a 2-fold dilution series of three replicates per concentration, and the lowest concentration that gave all three positive results was deemed as the LoD. Fifty (50) µL of the spiked samples were dispensed onto the sterile disposable swab provided in each test kit and eluted into the buffer solution following the manufacturer's Instructions for Use (IFU). A fixed amount of buffer, according to the IFU, was dispensed onto the test cassette. Results were interpreted at a fixed time after sample addition, according to the IFU. A line intensity score was given to each line (control, influenza A, influenza B, SARS-CoV-2, RSV, AdV and MP) by comparing it to a reference line intensity chart that had 12 shades, ranging from the lightest (0) to the darkest (12). A line intensity of 3 or higher was defined as positive. The LoD was reported as the TCID₅₀/mL or CCU/mL concentration in the PNW sample.

Parallel Comparison of assays:

The forementioned kits from INDICAID™, BioTeke™, and REAGEN® were tested with PNW spiked with strains of SARS-CoV-2, Influenza A&B, RSV, AdV and MP, respectively. Each virus strain was tested independently at 2-4 concentrations closest to the LoD of the INDICAID™ in triplicates. Aside from the contrived sample, all materials used in the test were provided in the respective kit. The test method and result interpretation were the same as those described in the LoD determination section.

A comprehensive rapid test for major severe respiratory virus in Hong Kong; product performance test among major brands

Test Kits

Manufacturer	Description
PHASE Scientific	INDICAID™ RESPIRATORY 6-in-1 Rapid Antigen Test
BioTeke™	BioTeke™ SARS-CoV-2/FluA/FluB/RSV/ADV/MP Antigen Test Kit (SARS-CoV-2 Flu A Flu B RSV ADV MP)
REAGEN®	REAGEN® SARS-CoV-2/RSV/ADV/MP&FluA/B Antigen Rapid Test Kit

Results

A total of 2 influenza A strains, 2 influenza B strains, 2 SARS-CoV-2 strains, 2 RSV strains, 2 Adv strains and 1 MP strain were evaluated.

For Influenza A test line performance comparison (Table 1 and 2), in the two strains of Influenza A tested, INDICAID™

outperformed BioTeke™ and REAGEN®. INDICAID™ exhibits 4 times better LoD than BioTeke™ while REAGEN® showing the weakest performance in detecting Influenza A H1N1 strain and was not able to produce a definite positive test result in all concentrations of the virus tested. In Influenza A H3N2, INDICAID™ exhibits 2 times better LoD than BioTeke™ and REAGEN®.

Table 1: Influenza A Test Results

Sub-type	Strain	Source	Product code	Concentration tested (TCID ₅₀ /mL)	Number of devices with positive result		
					INDICAID™	BioTeke™	REAGEN®
H1N1	A/California/7/2009	ZeptoMetrix®	0810165CF	141	3/3	3/3	1/3
				70.5	3/3	2/3	0/3
				35.25	3/3	0/3	0/3
				17.625	0/3	0/3	0/3
H3N2	A/Victoria/361/11	ZeptoMetrix®	0810240CF	38.9	3/3	3/3	3/3
				19.45	3/3	1/3	0/3
				9.725	1/3	0/3	0/3

Table 2: Influenza A LoD Results Summary

Product Number	Description	Limit of Detection concentration in PNW (TCID ₅₀ /mL) (Concentration before dilution in buffer)		
		INDICAID™	BioTeke™	REAGEN®
0810165CF	Influenza A (H1N1) A/California/7/2009	35.25	141	/
0810240CF	Influenza A (H3N2) A/Victoria/361/2011	19.45	38.9	38.9

For Influenza B test line performance comparison (Table 3 and 4), INDICAID™ outperformed BioTeke™, and REAGEN® on Influenza B. In the Influenza B (Victoria) B/Colorado/06/2017 strain, INDICAID™ exhibits 2 times better LoD than BioTeke™, while REAGEN® showed poorer performance and was not able to produce a definite positive test result in all concentrations of the virus tested. For the Influenza B (Yamagata) B/Phuket/3073/2013 strain,

INDICAID™ and BioTeke™ displayed consistent performance, while REAGEN® showed poorer performance and was not able to produce a definite positive test result in all concentrations of the virus tested. REAGEN® showed poorer performance in both Influenza B strains and was not able to produce a definite positive test result in all concentrations of the virus tested.

Table 3: Influenza B Test Results

Sub-type	Strain	Source	Product code	Concentration tested (TCID ₅₀ /mL)	Number of devices with positive result		
					INDICAID™	BioTeke™	REAGEN®
Victoria	B/Colorado/06/2017	ZeptoMetrix®	0810573CF	234	3/3	3/3	0/3
				117	3/3	0/3	0/3
				78	0/3	0/3	0/3
Yamagata	B/Phuket/3073/2013	ZeptoMetrix®	0810515CF	37.2	3/3	3/3	2/3
				18.6	0/3	0/3	0/3

Table 4: Influenza B LoD Results Summary

Product Number	Description	Limit of Detection concentration in PNW (TCID ₅₀ /mL) (Concentration before dilution in buffer)		
		INDICAID™	BioTeke™	REAGEN®
0810573CF	Influenza B (Victoria) B/Colorado/06/2017	117	234	/
0810515CF	Influenza B (Yamagata) B/Phuket/3073/2013	37.2	37.2	/

A comprehensive rapid test for major severe respiratory virus in Hong Kong; product performance test among major brands

For SARS-CoV-2 test line performance comparison (Table 5 and 6), INDICAID™ outperformed BioTeke™ and REAGEN®. In SAVS-CoV-2 USA-WA1/2020 strain, INDICAID™ exhibits 1.6 times better LoD than BioTeke™ in detecting the USA-WA1/2020 strain, while REAGEN® showed poorer performance and was not able to produce a definite

positive test result in all concentrations of the virus tested. INDICAID™ outperformed REAGEN® and consistent with BioTeke™ on the USA/CA-Stanford-109_S21/2022 strain. REAGEN® showed poorer performance in both SARS-CoV-2 strains and was not able to produce a definite positive test result in all concentrations of the virus tested.

Table 5: SARS-CoV-2 Test Results

Strain	Source	Product code	Concentration tested (TCID ₅₀ /mL)	Number of devices with positive result		
				INDICAID™	BioTeke™	REAGEN®
USA-WA1/2020	ZeptoMetrix®	0810587UV	1510	3/3	3/3	0/3
			945	3/3	0/3	0/3
			472.5	0/3	0/3	0/3
USA/CA-Stanford-109_S21/2022	ZeptoMetrix®	0810665CFHI	11900	3/3	3/3	2/3
			5950	2/3	0/3	0/3

Table 6: SARS-CoV-2 LoD Results Summary

Product Number	Description	Limit of Detection concentration in PNW (TCID ₅₀ /mL) (Concentration before dilution in buffer)		
		INDICAID™	BioTeke™	REAGEN®
0810587UV	2019-nCoV/USA-WA1/2020	945	1510	/
0810665CFHI	USA/CA-Stanford-109_S21/2022	11900	11900	/

For RSV test line performance comparison (Table 7 and 8) INDICAID™ has outperformed BioTeke™ and REAGEN®. INDICAID™ exhibits 4 times better LoD than REAGEN®, and showed similar performance to BioTeke™ in detecting the

Respiratory syncytial virus A (RSV-A) strain. For Respiratory syncytial virus B (RSV-B) detection, INDICAID™ exhibited 4 times better LoD than REAGEN® and 2 times better LoD than BioTeke™.

Table 7: RSV Test Results

Strain	Source	Product code	Concentration tested (TCID ₅₀ /mL)	Number of devices with positive result		
				INDICAID™	BioTeke™	REAGEN®
Respiratory syncytial virus A	ZeptoMetrix®	0810040ACF	501	3/3	3/3	3/3
			250.5	3/3	3/3	2/3
			125.25	3/3	3/3	0/3
			62.625	0/3	0/3	0/3
Respiratory syncytial virus B	ZeptoMetrix®	0810040CF	527	3/3	3/3	3/3
			263.5	3/3	3/3	1/3
			131.75	3/3	1/3	0/3
			65.875	1/3	0/3	0/3

Table 8: RSV LoD Results Summary

Product Number	Description	Limit of Detection concentration in PNW (TCID ₅₀ /mL) (Concentration before dilution in buffer)		
		INDICAID™	BioTeke™	REAGEN®
0810040ACF	Respiratory syncytial virus A	125.25	125.25	501
0810040CF	Respiratory syncytial virus B	131.75	263.5	527

For AdV test line performance comparison (Table 9 and 10) INDICAID™ outperformed BioTeke™ and REAGEN®. INDICAID™ exhibits 2 times better LoD than BioTeke™ and REAGEN® in detecting the AdV Type 1 strain. In detecting

AdV Type 7A, INDICAID™ showed a similar performance to BioTeke™ while REAGEN® was not able to produce a definite positive test result.

Table 9: AdV Test Results

Strain	Source	Product code	Concentration tested (TCID ₅₀ /mL)	Number of devices with positive result		
				INDICAID™	BioTeke™	REAGEN®
Type 1 (Species C)	ZeptoMetrix®	0810050CF	7050	3/3	3/3	3/3
			3525	3/3	2/3	0/3
			1762.5	0/3	0/3	0/3
Type 7A (Species B)	ZeptoMetrix®	0810021CF	790	3/3	3/3	2/3
			395	2/3	0/3	0/3

Table 10: AdV LoD Results Summary

Product Number	Description	Limit of Detection concentration in PNW (TCID ₅₀ /mL) (Concentration before dilution in buffer)		
		INDICAID™	BioTeke™	REAGEN®
0810050CF	Adenovirus Type 1	3525	7050	7050
0810021CF	Adenovirus Type 7A	790	790	/

For MP test line performance comparison (Table 11 and 12), INDICAID™ outperformed BioTeke™ and REAGEN®. INDICAID™ exhibits 4 times better LoD than BioTeke™,

while REAGEN® were not able to produce a definite positive test result in all concentrations of the MP tested.

Table 11: MP Test Results

Strain	Source	Product code	Concentration tested (CCU/mL)	Number of devices with positive result		
				INDICAID™	BioTeke™	REAGEN®
Mycoplasma pneumoniae	ZeptoMetrix®	0801579	31600	3/3	3/3	1/3
			15800	3/3	2/3	0/3
			7900	3/3	0/3	0/3
			3950	0/3	0/3	0/3

Table 12: MP LoD Results Summary

Product Number	Description	Limit of Detection concentration in PNW (TCID ₅₀ /mL) (Concentration before dilution in buffer)		
		INDICAID™	BioTeke™	REAGEN®
0801579	Mycoplasma pneumoniae	7900	31600	/

Conclusion

The accuracy of a self-test assay is influenced by two key factors: the sampling technique employed by the lay user and the sensitivity and specificity of the device itself⁽⁵⁾. Although manufacturers provide comprehensive instructions on sampling techniques through instructional materials or videos, it is challenging to ensure that lay users interpret and implement these instructions correctly. Therefore, it is crucial for manufacturers to enhance the sensitivity and specificity of their devices to improve the overall accuracy of the test results.

INDICAID™ RESPIRATORY 6-in-1 Rapid Antigen Test exhibited superior performance in all 11 strains of Influenza A, Influenza B, SARS-CoV-2, RSV, AdV and MP tested, compared to at least 1 of the 2 commonly available Hong Kong RAT brands tested, namely BioTeke™ SARS-CoV-2/FluA/FluB/RSV/ADV/MP Antigen Test Kit (SARS-CoV-2 | Flu A | Flu B | RSV | ADV | MP) and REAGEN® SARS-CoV-2/RSV/ADV/MP&FluA/B Antigen Rapid Test Kit.

Specifically, INDICAID™ consistently outperformed the other tests for the evaluated strains of Influenza A, demonstrating better sensitivity. For Influenza B, INDICAID™ showed superior performance for the Influenza B (Victoria) B/Colorado/06/2017 strain, while exhibiting comparable performance to BioTeke™^a for the Influenza B (Yamagata) B/Phuket/3073/2013 strain. For SARS-CoV-2, INDICAID™ outperformed BioTeke™ and REAGEN® in detecting the 2019-nCoV/USA-WA1/2020 strain. INDICAID™

outperformed and REAGEN®, and consistent with BioTeke™ on the USA/CA-Stanford-109_S21/2022 strain. For RSV, INDICAID™ outperformed REAGEN® and showed similar performance to BioTeke™ in detecting the Respiratory syncytial virus A (RSV-A) strain. For Respiratory syncytial virus B (RSV-B) detection, INDICAID™ outperformed REAGEN® and BioTeke™. For AdV, INDICAID™ had outperformed BioTeke™ and REAGEN® in detecting Adenovirus Type 1 strain. In detecting Adenovirus Type 7A, INDICAID™ outperformed REAGEN® and showed a similar performance to BioTeke™.

For MP, INDICAID™ outperformed BioTeke™ and REAGEN®, INDICAID™ exhibits 4 times better LoD than BioTeke™, while REAGEN® were not able to produce a definite positive test result in all concentrations of the Mycoplasma pneumoniae strain tested.

In conclusion, the INDICAID™ Respiratory 6-in-1 Rapid Antigen Test exhibited a better Limit of Detection (LoD) for influenza A, influenza B, SARS-CoV-2, RSV, AdV and MP compared to commonly available RAT brands in Hong Kong. A better LoD indicates that the test can detect infections at an earlier stage when the viral load in patients is still low. Early detection enables individuals to seek prompt treatment and self-isolation, thereby reducing the risk of transmitting the virus to others. These findings highlight the reliability and efficiency of INDICAID™ as a diagnostic tool for detecting multiple strains of influenza A, influenza B, SARS-CoV-2, RSV, AdV and MP, surpassing the performance of other market-leading brands.

References

1. A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. Junhao Luo, Zhuohan Zhang, Song Zhao, Rongbao Gao. March, s.l.: Int J Mol Sci, 2023, 24(7), 6369.
2. WHO Coronavirus (COVID-19) Dashboard. [Online] [Cited: 7 12, 2023.] <https://covid19.who.int/>.
3. Influenza A, Influenza B, and SARS-CoV-2 Similarities and Differences - A Focus on Diagnosis. Andrei Havasi, Simona Visan, Calin Cainap, Simona Sorana Cainap, Alin Adrian Mihaila, Laura-Ancuta Pop. s.l.: Front Microbiol, 2022, Vol. Jun 20:13:908525.
4. Influenza. Timothy M Uyeki, David S Hui, Maria Zambon, David E Wentworth, Arnold S Monto. s.l.: Lancet, 2022, Vol. 400, 693-706.
5. Diagnostic accuracy of covid-19 rapid antigen tests with unsupervised self-sampling in people with symptoms in the omicron period: cross sectional study. Schuit E, Venekamp RP, Hooff L, Veldhuijzen IK, van den Bijllaardt W, Pas SD, Zwart VF, Lodder EB, Hellwich M, Koppelman M, Molenkamp R, Wijers CJH, Vroom IH, Smeets LC, Nagel-Inming CRS, Han WGH, van den Hof S, Kluytmans JA JW, van de Wijert JHMM, Moons. s.l.: BMJ, 2022, Vol. Sep 14:378:e071215.
6. Clinical features of respiratory syncytial virus, human rhinovirus and mycoplasma pneumoniae infection in children with asthmatic diseases and analysis of risk factors for recurrent wheezing [D]. Zhichao Sun. Jiagsu: Soochow University, 2022.
7. Analysis of clinical characteristics of 150 cases of respiratory tract adenovirus infection in children [D]. Renfeng Wang. Wenzhou Medical University, 2019.